Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Glycyrrhizic Acid Alleviates Osimertinib‐Induced Cutaneous Toxicity by Inhibiting Keratinocyte Apoptosis and Inflammation
Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
research ISID1403 - Melatonin protects K15+ human hair follicle stem cells against paclitaxel-induced damage ex vivo
Melatonin may protect hair follicle stem cells from damage caused by chemotherapy.
research Selenium or No Selenium- That Is the Question in Tumor Patients: A New Controversy
There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.
research 213P Photobiomodulation therapy for the management of chemotherapy-induced alopecia: Preliminary results of a randomized, controlled trial
Photobiomodulation therapy may speed up hair regrowth after chemotherapy in the short term.
research Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis
Antizyme slows skin tumor growth by reducing cell growth in mice.
research Taxane-induced alopecia: A historical review of patients with ovarian or breast cancer treated with with paclitaxel, docetaxel or paclitaxel poliglumex
PPX causes much less hair loss than traditional taxanes.
research Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.